This document discusses embolic stroke of undetermined source (ESUS). It defines ESUS as an ischemic stroke that is not lacunar or cardioembolic in origin and with no significant arterial obstruction. The document then lists and describes various potential causes of ESUS including cardiac, infectious, inflammatory, hematological, and other less common etiologies. It also discusses diagnostic criteria and methods for ESUS, clinical aspects of patients with ESUS, and treatment options.
Austin Biomarkers & Diagnosis is a peer-reviewed, open access journal published by Austin Publishers. It provides easy access to high quality Manuscripts covering aspects of measure and evaluation to examine normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention. It also focus upon aspects of dynamic and powerful approaches in understanding the spectrum of disease with applications in observational and analytic epidemiology, randomized clinical trials, screening and diagnosis.
Austin Publishing Group is a successful host of more than hundred peer reviewed, open access journals in various fields of science and technology with intent to bridge the gap between academia and research access.
Austin Biomarkers & Diagnosis accepts original research articles, review articles, case reports, mini reviews, rapid communication, opinions and editorials on all the related aspects of biomarkers involved in normal biological processes, pathological process, and pharmacological responses as well as in diagnosing diseases.
Ponencia presentada por el Dr. J. Raúl Moreno Gómez en el directo 'Controversias en tratamiento antitrombótico – Parte II', realizado el 6 de abril de 2021
Austin Biomarkers & Diagnosis is a peer-reviewed, open access journal published by Austin Publishers. It provides easy access to high quality Manuscripts covering aspects of measure and evaluation to examine normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention. It also focus upon aspects of dynamic and powerful approaches in understanding the spectrum of disease with applications in observational and analytic epidemiology, randomized clinical trials, screening and diagnosis.
Austin Publishing Group is a successful host of more than hundred peer reviewed, open access journals in various fields of science and technology with intent to bridge the gap between academia and research access.
Austin Biomarkers & Diagnosis accepts original research articles, review articles, case reports, mini reviews, rapid communication, opinions and editorials on all the related aspects of biomarkers involved in normal biological processes, pathological process, and pharmacological responses as well as in diagnosing diseases.
Ponencia presentada por el Dr. J. Raúl Moreno Gómez en el directo 'Controversias en tratamiento antitrombótico – Parte II', realizado el 6 de abril de 2021
Cryptogenic stroke and PFO have always been a controversial topic with no closure trial in the past showing significant benefit from closing the PFO in preventing the recurrent stroke. Also thought to be due to imperfect definition of cryptogenic stroke which is evolving with drop in the fraction of patients from 20-40% in the past to very fewer numbers due to increased understanding of the mechanisms involved in acute stroke. Recent trials REDUCE and CLOSE targeted the niche population of PFO with moderate to large shunt and atrial septal aneurysm and showed benefit of closing PFO compared to the antiplatelet therapy alone but with the risk of A.fib, device and procedure related complications. This presentation is made in the Cerebrovascular center weekly conference at the Cleveland Clinic with my perspective after these current trials.
Thrombolysis and thrombectomy for acute ischaemic strokeHan Naung Tun
Reperfusion by intravenous thrombolysis or endovascular
mechanical thrombectomy improves functional outcomes
after stroke, but benefit for both treatment modalities is highly
time-dependent. Maximum benefit requires minimisation
of onset-to-treatment times. The safety and efficacy of IV
rtPA is established across a broad range of clinical scenarios.
Endovascular treatment now offers greatly improved outcome
among patients with poor response to IV rtPA but efficacy
has been established only in the context of highly organised
neurovascular interventional services.
Ponencia comentada por los doctores Esteban López de Sá y Areses y Ricard Ferrer Roca en el CardioTV Live ‘Control de temperatura tras el TTM2’, realizado en la Casa del Corazón el 20 de septiembre de 2021.
Rationale: Coronary artery spasm is common ischemic heart disease. It is a serious clinical cardiovascular issue. Nitrates such as nitroglycerine have a pivotal role in the management of coronary artery disease.
Patient concerns: A 45-year-old married, officer, heavy smoker, Egyptian male patient presented with acute excruciating severe chest pain and combined electrocardiographic ST-segment coronary artery spasms.
Diagnosis: Combined ST-segment coronary artery spasms of ST-segment elevations and ST-depressions were the most probable diagnosis.
Interventions: Electrocardiogram, echocardiography, and nitroglycerine intravenous infusion.
Outcomes: Dramatic response of both clinical and electrocardiographic combined ST-segment coronary artery spasms to nitroglycerine.
Lessons: A combined ST-segment coronary artery spasms including ST-segment elevation and ST-depression may be present in the same ECG. The dramatic efficacy of later using nitroglycerine in the management of combined ST-segment coronary artery spasms.
Cryptogenic stroke and PFO have always been a controversial topic with no closure trial in the past showing significant benefit from closing the PFO in preventing the recurrent stroke. Also thought to be due to imperfect definition of cryptogenic stroke which is evolving with drop in the fraction of patients from 20-40% in the past to very fewer numbers due to increased understanding of the mechanisms involved in acute stroke. Recent trials REDUCE and CLOSE targeted the niche population of PFO with moderate to large shunt and atrial septal aneurysm and showed benefit of closing PFO compared to the antiplatelet therapy alone but with the risk of A.fib, device and procedure related complications. This presentation is made in the Cerebrovascular center weekly conference at the Cleveland Clinic with my perspective after these current trials.
Thrombolysis and thrombectomy for acute ischaemic strokeHan Naung Tun
Reperfusion by intravenous thrombolysis or endovascular
mechanical thrombectomy improves functional outcomes
after stroke, but benefit for both treatment modalities is highly
time-dependent. Maximum benefit requires minimisation
of onset-to-treatment times. The safety and efficacy of IV
rtPA is established across a broad range of clinical scenarios.
Endovascular treatment now offers greatly improved outcome
among patients with poor response to IV rtPA but efficacy
has been established only in the context of highly organised
neurovascular interventional services.
Ponencia comentada por los doctores Esteban López de Sá y Areses y Ricard Ferrer Roca en el CardioTV Live ‘Control de temperatura tras el TTM2’, realizado en la Casa del Corazón el 20 de septiembre de 2021.
Rationale: Coronary artery spasm is common ischemic heart disease. It is a serious clinical cardiovascular issue. Nitrates such as nitroglycerine have a pivotal role in the management of coronary artery disease.
Patient concerns: A 45-year-old married, officer, heavy smoker, Egyptian male patient presented with acute excruciating severe chest pain and combined electrocardiographic ST-segment coronary artery spasms.
Diagnosis: Combined ST-segment coronary artery spasms of ST-segment elevations and ST-depressions were the most probable diagnosis.
Interventions: Electrocardiogram, echocardiography, and nitroglycerine intravenous infusion.
Outcomes: Dramatic response of both clinical and electrocardiographic combined ST-segment coronary artery spasms to nitroglycerine.
Lessons: A combined ST-segment coronary artery spasms including ST-segment elevation and ST-depression may be present in the same ECG. The dramatic efficacy of later using nitroglycerine in the management of combined ST-segment coronary artery spasms.
Valsalva manoeuvre in drug refractory ventricular tachycardiaRamachandra Barik
Ventricular tachycardia (VT) is a cardiac emergency exerting significant morbidity and mortality. Differentiation between VT and supraventricular tachycardia with aberrancy (SVT-A) can be challenging,necessitating awareness of the salient lectrocardiogram (ECG)criteria1 and at times, proven refractoriness to adenosine. Despite well-established guidelines and evidence-based anti-arrhythmic medications for VT management, the role of Valsalva manoeuvre (VM) as
an effective treatment for VT remains controversial.2,3 In this case report, we describe a patient who presented with multiple
drug-refractory VTs, one of which repeatedly terminated by VM.
Basavarajeeyam is a Sreshta Sangraha grantha (Compiled book ), written by Neelkanta kotturu Basavaraja Virachita. It contains 25 Prakaranas, First 24 Chapters related to Rogas& 25th to Rasadravyas.
CDSCO and Phamacovigilance {Regulatory body in India}NEHA GUPTA
The Central Drugs Standard Control Organization (CDSCO) is India's national regulatory body for pharmaceuticals and medical devices. Operating under the Directorate General of Health Services, Ministry of Health & Family Welfare, Government of India, the CDSCO is responsible for approving new drugs, conducting clinical trials, setting standards for drugs, controlling the quality of imported drugs, and coordinating the activities of State Drug Control Organizations by providing expert advice.
Pharmacovigilance, on the other hand, is the science and activities related to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems. The primary aim of pharmacovigilance is to ensure the safety and efficacy of medicines, thereby protecting public health.
In India, pharmacovigilance activities are monitored by the Pharmacovigilance Programme of India (PvPI), which works closely with CDSCO to collect, analyze, and act upon data regarding adverse drug reactions (ADRs). Together, they play a critical role in ensuring that the benefits of drugs outweigh their risks, maintaining high standards of patient safety, and promoting the rational use of medicines.
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
1. ECV DE CAUSA INHABITUAL
Ponente: Dr José Gallardo
R1 Medicina Interna
Tutor: Dr Yimber Matos
Médico Neurólogo
San Cristobal, Febrero 2022
Classification of subtype of acute ischemic stroke, Definitions
for use in a multicenter clinical trial. TOAST. Trial of Org 10172
in Acute Stroke Treatment.
2. ECV DE CAUSA INHABITUAL (ESUS)
Acrónimo en inglés para embolic stroke of unknown source
• No lacunar
• No cardioembólico
• Sin obstruccion aterotrombótica significativa
Classification of subtype of acute ischemic stroke, Definitions
for use in a multicenter clinical trial. TOAST. Trial of Org 10172
in Acute Stroke Treatment.
3. ECV DE CAUSA INHABITUAL (ESUS)
• Enfermedad valvular
• Prolapso mitral
• Endocarditis de Libman-Sacks (ELS)
• Defectos de Septum y foramen oval
• Calcificación de anillo valvular aórtico
Cardiaco
• Fibrilación auricular paroxística
• Placas ulceradas no estenosantes en vasos cervicales
• Valvulopatía mixomatosa con prolapso mitral
No frecuentes
Classification of subtype of acute ischemic stroke, Definitions
for use in a multicenter clinical trial. TOAST. Trial of Org 10172
in Acute Stroke Treatment.
ETIOLOGÍA
4. ECV DE CAUSA INHABITUAL (ESUS)
Classification of subtype of acute ischemic stroke, Definitions
for use in a multicenter clinical trial. TOAST. Trial of Org 10172
in Acute Stroke Treatment.
• Chagas
• Toxoplasmosis
• Mucormicosis
• Difteria
• Sífilis
• Hiv
• Tbc
• cisticercosis
Infecciones
• Vasculitis
• Hodgkin
• Colitis ulcerativa
• Granuloma linfomatoide
Inflamatorias
• Malformaciones arteriovenosas pulmonares
(MAVP)
• Fistula arteriovenosa pulmonar (ROW)
• Tu pulmonar y mediastínico
Pulmonares
5. ECV DE CAUSA INHABITUAL (ESUS)
Classification of subtype of acute ischemic stroke, Definitions
for use in a multicenter clinical trial. TOAST. Trial of Org 10172
in Acute Stroke Treatment.
• Purpura trombocitopenica
• Anticoagulante lúpico
• Anticuerpos anticardiolipina
Inmunológicas
• Anemia drepanocítica
• Policitemia vera
• Trombosis primaria
• Talasemia
Hiperviscosidad
• CID
• Déficit de AT III, Prot C y S, Factor VII
• Sx Paraneoplasicos
• ACO
Trastornos de
coagulación
HEMATOLOGICAS
6. ECV DE CAUSA INHABITUAL (ESUS)
Classification of subtype of acute ischemic stroke, Definitions
for use in a multicenter clinical trial. TOAST. Trial of Org 10172
in Acute Stroke Treatment.
• Migraña
• Fármacos
• Drogas
Vasoespasmo
• Síndrome de Marfán
• Síndrome de Ehler-Danlos
• Fabry
Congénitas
• Enfermedad Moya Moya
• Síndrome de Sneddon
• Radiación
Otras causas
7. ECV DE CAUSA INHABITUAL (ESUS)
Classification of subtype of acute ischemic stroke, Definitions
for use in a multicenter clinical trial. TOAST. Trial of Org 10172
in Acute Stroke Treatment.
Cáncer y ECV
SINDROME DE TROUSSEAU
• Cáncer de pulmón.
• Cáncer mamario.
• Cáncer de colon.
• Cáncer de riñón.
• Melanoma
• Cistoadenocarcinoma de páncreas
8. ECV DE CAUSA INHABITUAL (ESUS)
Classification of subtype of acute ischemic stroke, Definitions
for use in a multicenter clinical trial. TOAST. Trial of Org 10172
in Acute Stroke Treatment.
Criterios diagnósticos para ACV embólico de origen indeterminado (ESUS)
• ACV isquémico (no lacunar) en tomografía o resonancia cerebral
• Ausencia de estenosis arterial superior al 50% de vasos cervicales o intracraneales
• Ausencia de origen cardioembólico de alto riesgo
• Ausencia de otra causa específica de ACV (arteritis, disección, migraña/vasoespasmo
9. ECV DE CAUSA INHABITUAL (ESUS)
Classification of subtype of acute ischemic stroke, Definitions
for use in a multicenter clinical trial. TOAST. Trial of Org 10172
in Acute Stroke Treatment.
Métodos diagnósticos para detección de ACV embólico de origen indeterminado (ESUS)a
• Tomografía o resonancia cerebral
• Electrocardiograma de 12 derivaciones
• Telemetría cardiaca con detección automática de ritmo cardiaco por 24h
• Imagen vascular de la arteria involucrada en el territorio del ACV isquémico (ultrasonografía, angiorresonancia,
angiotomografía o angiografía digital)
• Ecocardiograma transtorácico y/o transesofágico
10. ECV DE CAUSA INHABITUAL (ESUS)
Classification of subtype of acute ischemic stroke, Definitions
for use in a multicenter clinical trial. TOAST. Trial of Org 10172
in Acute Stroke Treatment.
Aspectos clínicos de los pacientes con ESUS:
• Edad y no sexo como predictor de recurrencias
• Riesgo aumentado 3-8 veces en personas >80 años
• ¿A quien anticoagulamos?
11. ECV DE CAUSA INHABITUAL (ESUS)
Classification of subtype of acute ischemic stroke, Definitions
for use in a multicenter clinical trial. TOAST. Trial of Org 10172
in Acute Stroke Treatment.
12. ECV DE CAUSA INHABITUAL (ESUS)
Classification of subtype of acute ischemic stroke, Definitions
for use in a multicenter clinical trial. TOAST. Trial of Org 10172
in Acute Stroke Treatment.
Terapéutica antitrombótica en pacientes con ESUS
• Estudio WARSS
• Evidencia de disminución de disminución de recurrencias en pacientes con
anticoagulación frente a pacientes con antiagregacion
13. ECV DE CAUSA INHABITUAL (ESUS)
Classification of subtype of acute ischemic stroke, Definitions
for use in a multicenter clinical trial. TOAST. Trial of Org 10172
in Acute Stroke Treatment.
14. ECV DE CAUSA INHABITUAL (ESUS)
Classification of subtype of acute ischemic stroke, Definitions
for use in a multicenter clinical trial. TOAST. Trial of Org 10172
in Acute Stroke Treatment.
CAUSAS
INFECCIOSA
• TBC
• Herpes zoster
• Cisticercosis
• Sífilis
• Mucormicosis
• Bacteriana
NO
INFECCIOSA
• Takayasu
• Temporal de células gigantes
• Panarteritis nodosa
• LES
• Sjögren
• Wegener
15. ECV DE CAUSA INHABITUAL (ESUS)
Classification of subtype of acute ischemic stroke, Definitions
for use in a multicenter clinical trial. TOAST. Trial of Org 10172
in Acute Stroke Treatment.
DISECCIÓN ARTERIAL
16. ECV DE CAUSA INHABITUAL (ESUS)
Classification of subtype of acute ischemic stroke, Definitions
for use in a multicenter clinical trial. TOAST. Trial of Org 10172
in Acute Stroke Treatment.
Disección arterial:
2-22%
2da mas frecuente en jóvenes
Mas frecuente en carótida interna (75%)
Espontáneo o traumático
Relacionado con displasia fibromuscular
17. ECV DE CAUSA INHABITUAL (ESUS)
Classification of subtype of acute ischemic stroke, Definitions
for use in a multicenter clinical trial. TOAST. Trial of Org 10172
in Acute Stroke Treatment.
ENFERMEDAD DE MOYA MOYA
18. ECV DE CAUSA INHABITUAL (ESUS)
Classification of subtype of acute ischemic stroke, Definitions
for use in a multicenter clinical trial. TOAST. Trial of Org 10172
in Acute Stroke Treatment.
VASCULOPATÍA INTRACRANEAL OCLUSIVA NO INFLAMATORIA
• Bilateral
• Entre la 1 y 4ta década de la vida
• Sin clínica específica
19. ECV DE CAUSA INHABITUAL (ESUS)
Classification of subtype of acute ischemic stroke, Definitions
for use in a multicenter clinical trial. TOAST. Trial of Org 10172
in Acute Stroke Treatment.
SÍNDROME DE SNEDDON
20. ECV DE CAUSA INHABITUAL (ESUS)
Classification of subtype of acute ischemic stroke, Definitions
for use in a multicenter clinical trial. TOAST. Trial of Org 10172
in Acute Stroke Treatment.
SÍNDROME DE SNEDDON
Diagnostico de exclusión
Relacion > mujeres-Hombres
Lívedo reticularis
AIT
Demencia vascular
Isquemia periférica en miembros
21. ECV DE CAUSA INHABITUAL (ESUS)
Classification of subtype of acute ischemic stroke, Definitions
for use in a multicenter clinical trial. TOAST. Trial of Org 10172
in Acute Stroke Treatment.
MIGRAÑA
22. ECV DE CAUSA INHABITUAL (ESUS)
Classification of subtype of acute ischemic stroke, Definitions
for use in a multicenter clinical trial. TOAST. Trial of Org 10172
in Acute Stroke Treatment.
MIGRAÑA
Historia previa
Déficit neurológico focal >24hrs
Presencia de isquemia en imágenes
Ausencia de otra causa
23. ECV DE CAUSA INHABITUAL (ESUS)
Classification of subtype of acute ischemic stroke, Definitions
for use in a multicenter clinical trial. TOAST. Trial of Org 10172
in Acute Stroke Treatment.
Otras causas:
CRACK
ISQUEMIA
COCAÍNA
HEMORRAGIA •ECV((18-33%)
•80-90% Entre
la 3ra y 4ta
década de la
vida
24. ECV DE CAUSA INHABITUAL (ESUS)
Classification of subtype of acute ischemic stroke, Definitions
for use in a multicenter clinical trial. TOAST. Trial of Org 10172
in Acute Stroke Treatment.
RADIOTERAPIA
EXTRACRANEAL: Ateroesclerosis acelerada
INTRACRANEAL: Lesión de pequeños vasos
25. ECV DE CAUSA INHABITUAL (ESUS)
Classification of subtype of acute ischemic stroke, Definitions
for use in a multicenter clinical trial. TOAST. Trial of Org 10172
in Acute Stroke Treatment.